The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents-Reference-Cited by-同舟云学术

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Published:2022-01-05 Issue:8 Volume:71 Page:1823-1835
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Zamora Atenza Carlos,Anguera Geòrgia,Riudavets Melià Mariona,Alserawan De Lamo Letícia,Sullivan Ivana,Barba Joaquin Andrés,Serra Lopez Jorgina,Ortiz M. Angels,Mulet Maria,Vidal Sílvia,Majem Margarita^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03107-y.pdf

Reference34 articles.

1. Nixon NA, Blais N, Ernst S et al (2018) Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 25:e373–e384. https://doi.org/10.3747/co.25.3840

2. Bocanegra A, Blanco E, Fernandez-Hinojal G et al (2020) PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy. Int J Mol Sci 21:1–17

3. Hui R, Gandhi L, Carcereny Costa E et al (2016) Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol 34:9026–9026. https://doi.org/10.1200/jco.2016.34.15_suppl.9026